New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long ...
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
STORY: Shares of Amgen on Tuesday were on track for their biggest percentage fall in more than two decades after the ...
Key TakeawaysA Phase 2 study of Amgen's experimental weight-loss treatment didn't meet expectations of analysts.Concerns were ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback